Peer Re­view: Eye­ing a $350M ven­ture fund, Nex­tech re­cruits Third Rock’s Jakob Loven for the team

Nex­tech In­vest closed its fourth on­col­o­gy ven­ture fund in 2014 with $64 mil­lion, putting it in­to play at a transat­lantic group of can­cer drug de­vel­op­ers. But this time around, they’re go­ing for $350 mil­lion for fund five, and they’ve re­cruit­ed a for­mer Third Rock alum — Jakob Loven — as a new part­ner to help man­age that in­vest­ment.

Loven was on the found­ing Third Rock team that helped set up Re­lay Phar­ma­ceu­ti­cals, a start­up fo­cused on pro­tein dy­nam­ics, right af­ter he was found­ing sci­en­tist at Sy­ros. And he crossed the globe to get his ed­u­ca­tion: Uni­ver­si­ty of Cam­bridge, the Karolin­s­ka In­sti­tute and the White­head In­sti­tute for his post­doc.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.